Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: Network is unreachable
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Cefepime, a fourth-generation cephalosporin, is widely used in the treatment of infections caused by resistant Gram-negative bacteria especially , or in severe infections, septic shock, and infections in immunocompromised patients. As it crosses the blood-brain barrier, it can cause neurotoxicity which has mostly been reported in patients with impaired renal function. Patients can present with drowsiness, confusion, delirium, agitation, stupor, or coma, and sometimes with generalized myoclonus and seizures within two to six days after starting the antibiotic. This is a rare case report where a patient with intact kidney function presented with confusion and incoherence. After excluding the possible causes for encephalopathy, cefepime-induced encephalopathy was diagnosed and the patient gradually improved after discontinuing the medication. This case is an unusual presentation of symptoms in a patient with normal kidney function, which necessitates further studies to establish other potential risk factors of cefepime-induced neurotoxicity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972131 | PMC |
http://dx.doi.org/10.1155/crdi/6650287 | DOI Listing |